Trial Profile
An Open-Label, Sequential-Group, Dose-Escalation Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Tecadenoson Alone and in Combination With a Beta-Blocker in Adults With Rapid Atrial Fibrillation (CVT 4129)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs Tecadenoson (Primary) ; Esmolol
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors CV Therapeutics; Gilead Sciences
- 05 Aug 2008 New trial record.